Clinical Trials Directory

Trials / Completed

CompletedNCT01293487

Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.

A PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF RN564 IN WOMEN WITH OSTEOPENIA AND IN HEALTHY MEN

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
68 (actual)
Sponsor
Pfizer · Industry
Sex
All
Age
55 Years – 80 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine the safety and tolerability of RN564 in women with osteopenia and healthy men.

Conditions

Interventions

TypeNameDescription
BIOLOGICALRN564Intravenous, single dose with experimental dose

Timeline

Start date
2011-04-01
Primary completion
2012-05-24
Completion
2012-05-24
First posted
2011-02-10
Last updated
2024-09-24
Results posted
2024-09-24

Locations

8 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01293487. Inclusion in this directory is not an endorsement.